Advertisement
The Essential Resource for the Medical Design Engineering Community
Subscribe to MDT Magazine All

IDEV Technologies Launches Additional Products in Europe

October 21, 2010 3:34 am | by Bio-Medicine.Org | News | Comments

WEBSTER, Texas, Oct. 21 /- IDEV Technologies, Incorporated (IDEV), an innovative leader in the development and commercialization of minimally invasive medical technologies, today announced another step in the implementation of its strategy to expand its product line for treating patients...

TOPICS:

Danaher Reports Record Third Quarter 2010 Results

October 21, 2010 3:34 am | by Bio-Medicine.Org | News | Comments

WASHINGTON, Oct. 21 /- Danaher Corporation (NYSE: DHR ) announced today that GAAP net earnings for the quarter ended October 1, 2010 were $646.4 million, or $0.95 per diluted share, which includes a $0.34 gain related to the formation of the Apex Tool Group joint venture, and represents a...

TOPICS:

DNA minivectors provide new gene therapy tool

October 21, 2010 3:33 am | by Baylor College of Medicine | News | Comments

Tiny wound-up circular bits of DNA that carry a short "hairpin" of RNA could prove a solution to the quest for a non-toxic, long-lived gene therapy vector designed to silence cancer genes in tumor cells, said researchers from Baylor College of Medicine and The Methodist Hospital Research...

TOPICS:
Advertisement

Researchers develop first implanted device to treat balance disorder

October 21, 2010 3:32 am | by EurekAlert | News | Comments

(University of Washington) A University of Washington Medical Center patient on Thursday, Oct. 21, will be the world's first recipient of a device that aims to quell the disabling vertigo associated with Meniere's disease. The UW Medicine clinicians who developed the implantable device...

TOPICS:

Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor

October 21, 2010 1:32 am | by Bio-Medicine.Org | News | Comments

LONDON, Oct. 21 /- Shionogi-ViiV Healthcare LLC today announced the start of the Phase III clinical programme evaluating its once-daily, unboosted investigational integrase inhibitor, S/GSK1349572 ('572). The Phase III clinical programme, which began this month, includes two studies...

TOPICS:

Intercell and Romark Join Forces in Combining Therapies Against Hepatitis C

October 21, 2010 1:31 am | by Bio-Medicine.Org | News | Comments

VIENNA, Oct. 21 /- Intercell AG (VSE; "ICLL") and Romark Laboratories L.C. today announced plans to commence clinical trials of Intercell's investigational therapeutic Hepatitis C virus (HCV) vaccine, IC41, in combination with Romark's antiviral drug, nitazoxanide, during the first half...

TOPICS:

Freescale accelerates automotive safety with advanced airbag sensors

October 20, 2010 11:33 pm | by I-Micronews | News | Comments

Xtrinsic sensors support the DSI 2.5 protocol, providing a smaller footprint and reduced time to market for cost-effective passenger safety

InvenSense to expand international presence at Dubai Silicon Oasis

October 20, 2010 11:33 pm | by I-Micronews | News | Comments

Dubai Silicon Oasis (DSO), the region's premier integrated innovations hub for high-technology industries, today announced InvenSense, Inc., the leading provider of MEMS-based motion processing solutions for consumer electronics, established its international sales headquarters within the...

Advertisement

Conventional, annual Pap smear cost-effective follow-up after cervical lesion treatment

October 20, 2010 9:33 pm | by EurekAlert | News | Comments

(University of California -- Davis - Health System) A study of the options for reducing cancer incidence and mortality among women who have been treated for precancerous cervical lesions found that an annual conventional Pap smear is a cost effective strategy.

TOPICS:

Virtual colonoscopy and teleradiology bring colorectal cancer screening to patients in rural areas

October 20, 2010 9:33 pm | by EurekAlert | News | Comments

(American College of Radiology / American Roentgen Ray Society) Computed tomography colonography (CTC) -- otherwise known as virtual colonoscopy -- is feasible in remote health centers where optimal colonoscopy is limited, according to a study in the November issue of the American...

TOPICS:

FDA approves Boehringer Ingelheim blood clot treatment

October 20, 2010 5:33 pm | by Mass High Tech: The Journal of New England Technology | News | Comments

The U.S. Food and Drug Administration has approved Pradaxa, a drug developed by Boehringer Ingelheim Corp. to lower the risk of stroke and blood clots in patients with irregular heartbeats.

TOPICS:

Vascular Solutions 3Q profit up slightly on sales

October 20, 2010 2:45 pm | by The Associated Press | News | Comments

Medical device maker Vascular Solutions Inc. said Wednesday its third-quarter net income rose slightly as higher revenue outpaced higher costs.Profit rose to just under $1.5 million, or 9 cents per share, from just over $1.4 million, or 9 cents per share, during the same period a year prior....

Vascular Solutions buys product line for $6.5M

October 20, 2010 2:45 pm | by The Associated Press | News | Comments

Vascular Solutions Inc. said Wednesday it bought assets related to the cardiovascular surgery products Expro Elite and Micro Elite from Radius Medical Technologies for about $6.5 million in cash.Vascular Solutions has been selling the products in the U.S. under a distribution relationship with...

TSX-listed corporate dividends and distributions declared Oct. 20, 2010

October 20, 2010 1:45 pm | by The Associated Press | News | Comments

Dividends or distributions were declared or updated on the followed listed issues on the Toronto Stock Exchange on October 20, 2010.Big Bank Big Oil Split Corp. Cl (TSX:BBO): $0.08. Payable Nov 12. Record Oct 29.Claymore Advantaged Cdn Bond Etf Units (TSX:CAB): $0.055. Payable Nov 04. Record...

GnRH Agonists: Label Change - Increased Risk of Diabetes and Cardiovascular Disease (Update)(2)

October 20, 2010 1:31 pm | by U.S. Food & Drug Administration | News | Comments

New information warns about increased risk of diabetes and certain cardiovascular diseases (heart attack, sudden cardiac death, stroke) in men receiving these medications for the treatment of prostate cancer.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading